Literature DB >> 28607501

Prostate cancer: Draft USPSTF 2017 recommendation on PSA testing - a sea-change?

Theodorus H Van der Kwast1, Monique J Roobol2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28607501     DOI： 10.1038/nrurol.2017.89

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

Authors:  Sigrid Carlsson; Andrew J Vickers; Monique Roobol; James Eastham; Peter Scardino; Hans Lilja; Jonas Hugosson
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

2.  Prostate cancer: Growth of AS in the USA signals reduction in overtreatment.

Authors:  Declan G Murphy; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2015-09-22       Impact factor: 14.432

3.  The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment.

Authors:  Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry
Journal:  JAMA       Date:  2017-05-16       Impact factor: 56.272

Review 4.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Authors:  Katherine Fleshner; Sigrid V Carlsson; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2016-12-20       Impact factor: 14.432

5.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

6.  A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.

Authors:  Leonard P Bokhorst; Riccardo Valdagni; Antti Rannikko; Yoshiyuki Kakehi; Tom Pickles; Chris H Bangma; Monique J Roobol
Journal:  Eur Urol       Date:  2016-06-19       Impact factor: 20.096

7.  Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Authors:  Carlotta Buzzoni; Anssi Auvinen; Monique J Roobol; Sigrid Carlsson; Sue M Moss; Donella Puliti; Harry J de Koning; Chris H Bangma; Louis J Denis; Maciej Kwiatkowski; Marcos Lujan; Vera Nelen; Alvaro Paez; Marco Randazzo; Xavier Rebillard; Teuvo L J Tammela; Arnauld Villers; Jonas Hugosson; Fritz H Schröder; Marco Zappa
Journal:  Eur Urol       Date:  2015-03-16       Impact factor: 20.096

Review 8.  Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.

Authors:  Renu S Eapen; Annika Herlemann; Samuel L Washington; Matthew R Cooperberg
Journal:  Curr Opin Urol       Date:  2017-05       Impact factor: 2.309

9.  National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.

Authors:  Michael W Drazer; Sandip M Prasad; Dezheng Huo; Mara A Schonberg; William Dale; Russell Z Szmulewitz; Scott E Eggener
Journal:  Cancer       Date:  2014-02-12       Impact factor: 6.860

10.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321
  10 in total
  5 in total

Review 1.  Future Perspectives and Challenges of Prostate MR Imaging.

Authors:  Baris Turkbey; Peter L Choyke
Journal:  Radiol Clin North Am       Date:  2017-12-09       Impact factor: 2.303

Review 2.  Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer.

Authors:  Jan Tkac; Veronika Gajdosova; Stefania Hroncekova; Tomas Bertok; Michal Hires; Eduard Jane; Lenka Lorencova; Peter Kasak
Journal:  Interface Focus       Date:  2019-02-15       Impact factor: 3.906

3.  Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core.

Authors:  Tomas Bertok; Lenka Lorencova; Stefania Hroncekova; Veronika Gajdosova; Eduard Jane; Michal Hires; Peter Kasak; Ondrej Kaman; Roman Sokol; Vladimir Bella; Anita Andicsova Eckstein; Jaroslav Mosnacek; Alica Vikartovska; Jan Tkac
Journal:  Biosens Bioelectron       Date:  2019-02-01       Impact factor: 12.545

4.  Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.

Authors:  Debashis Sahoo; Wei Wei; Heidi Auman; Antonio Hurtado-Coll; Peter R Carroll; Ladan Fazli; Martin E Gleave; Daniel W Lin; Peter S Nelson; Jeff Simko; Ian M Thompson; Robin J Leach; Dean A Troyer; Lawrence D True; Jesse K McKenney; Ziding Feng; James D Brooks
Journal:  Oncotarget       Date:  2018-01-05

5.  Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years.

Authors:  Heloise Schmeltz; Sylvain Rocher; Cédric Rat; France Nanin; Aurélie Gaultier; Jean-Michel Nguyen
Journal:  JMIR Public Health Surveill       Date:  2018-10-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.